Galmed Research and Development Ltd.

16 Tiomkin, Tel Aviv-Jaffa, Central District, Israel

Clinical Trials

4 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

62.5%

Phase 2

25.0%

Phase 3

12.5%

Trial Status Distribution

Active, not recruiting

50.0%

Completed

25.0%

Suspended

12.5%

Withdrawn

12.5%

Clinical Trials

Trials sponsored by this organization (8)

A Study Evaluating the Safety, Tolerability, and Efficacy of Aramchol Meglumine in Primary Sclerosing Cholangitis

Phase 2

Withdrawn

interventional

Jun 202524 participants

Open-Label Study to Evaluate the Safety, Tolerability, and PK of Aramchol in Subjects With Hepatic Impairment

Phase 1

Completed

interventional

Feb 202057 participants

A study to investigate the efficacy and safety of Aramchol in patients with a form of fatty liver disease.

Phase 1

Active, not recruiting

Nov 20192,000 participants

A study to investigate the efficacy and safety of Aramchol in patients with a form of fatty liver disease.

Phase 1

Active, not recruiting

interventional

Oct 20192,000 participants

A Clinical Study to Evaluate the Efficacy and Safety of Aramchol in Subjects With NASH (ARMOR)

Phase 3

Suspended

interventional

Sep 2019157 participants

A study to investigate the efficacy and safety of Aramchol in patients with a form of fatty liver disease.

Phase 1

Active, not recruiting

Sep 20192,000 participants

A study to investigate the efficacy and safety of Aramchol in patients with a form of fatty liver disease.

Phase 1

Active, not recruiting

Sep 20192,000 participants

A Clinical Trial to Evaluate the Efficacy and Safety of Two Aramchol Doses Versus Placebo in Patients With NASH

Phase 2

Completed

interventional

Apr 2015247 participants

Approvals

No approval data available

News

No news articles found

Back to Organizations